Literature DB >> 27791392

Impact of Ataxin-2 knock out on circadian locomotor behavior and PER immunoreaction in the SCN of mice.

Martina Pfeffer1,2, Suzana Gispert3, Georg Auburger3, Helmut Wicht1, Horst-Werner Korf1,2.   

Abstract

In Drosophila melanogaster, Ataxin-2 is a crucial activator of Period and is involved in the control of circadian rhythms. However, in mammals the function of Ataxin-2 is unknown despite its involvement in the inherited neurogenerative disease Spinocerebellar Ataxia type 2 in humans. Therefore, we analyzed locomotor behavior of Atxn2-deficient mice and their WT littermates under entrained- and free-running conditions as well as after experimental jet lag. Furthermore, we compared the PER1 and PER2 immunoreaction (IR) in the SCN. Atxn2-/- mice showed an unstable rhythmicity of locomotor activity, but the level of PER1 and PER2 IR in the SCN did not differ between genotypes.

Entities:  

Keywords:  Endogenous clock; PER1; PER2; SCA2; spinocerebellar ataxia type 2

Mesh：

Substances：

Year:  2016        PMID： 27791392     DOI： 10.1080/07420528.2016.1245666

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN： 0742-0528            Impact factor:   2.877


  8 in total

Review 1.  Ataxin-2: From RNA Control to Human Health and Disease.

Authors:  Lauren A Ostrowski; Amanda C Hall; Karim Mekhail
Journal:  Genes (Basel)       Date:  2017-06-05       Impact factor: 4.096

Review 2.  Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches.

Authors:  Luis C Velázquez-Pérez; Roberto Rodríguez-Labrada; Juan Fernandez-Ruiz
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

3.  In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism.

Authors:  Nesli-Ece Sen; Aleksandar Arsovic; David Meierhofer; Susanne Brodesser; Carola Oberschmidt; Júlia Canet-Pons; Zeynep-Ece Kaya; Melanie-Vanessa Halbach; Suzana Gispert; Konrad Sandhoff; Georg Auburger
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

4.  ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity.

Authors:  Qi Wang; Tianyu Cao; Xiaohui Zhang; Juan Hui; Chen Wang; Wenyao Zhang; Pei Wang; Yun Zhou; Shuang Han
Journal:  J Immunol Res       Date:  2022-09-28       Impact factor: 4.493

5.  Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.

Authors:  Huân M Ngô; Ying Zhou; Hernan Lorenzi; Kai Wang; Taek-Kyun Kim; Yong Zhou; Kamal El Bissati; Ernest Mui; Laura Fraczek; Seesandra V Rajagopala; Craig W Roberts; Fiona L Henriquez; Alexandre Montpetit; Jenefer M Blackwell; Sarra E Jamieson; Kelsey Wheeler; Ian J Begeman; Carlos Naranjo-Galvis; Ney Alliey-Rodriguez; Roderick G Davis; Liliana Soroceanu; Charles Cobbs; Dennis A Steindler; Kenneth Boyer; A Gwendolyn Noble; Charles N Swisher; Peter T Heydemann; Peter Rabiah; Shawn Withers; Patricia Soteropoulos; Leroy Hood; Rima McLeod
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

6.  Impaired Photic Entrainment of Spontaneous Locomotor Activity in Mice Overexpressing Human Mutant α-Synuclein.

Authors:  Martina Pfeffer; Zuzana Zimmermann; Suzana Gispert; Georg Auburger; Horst-Werner Korf; Charlotte von Gall
Journal:  Int J Mol Sci       Date:  2018-06-03       Impact factor: 5.923

7.  Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

Authors:  Amanjot Singh; Joern Hulsmeier; Arvind Reddy Kandi; Sai Shruti Pothapragada; Jens Hillebrand; Arnas Petrauskas; Khushboo Agrawal; Krishnan Rt; Devasena Thiagarajan; Deepa Jayaprakashappa; K VijayRaghavan; Mani Ramaswami; Baskar Bakthavachalu
Journal:  Elife       Date:  2021-03-10       Impact factor: 8.140

8.  The ATXN2 Orthologs CID3 and CID4, Act Redundantly to In-Fluence Developmental Pathways throughout the Life Cycle of Arabidopsis thaliana.

Authors:  Zaira M López-Juárez; Laura Aguilar-Henonin; Plinio Guzmán
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.